New AHA/ACC Blood Cholesterol Management Guidelines
New Blood Cholesterol Management Guidelines. This weekend, the American College of Cardiology (ACC) and the American Heart Association (AHA) published an… more
Posted by mlowe@esperion.comPOSITIVELY PRECISE.
We’re developing targeted therapies to lower LDL-cholesterol for patients not adequately treated with current lipid-modifying therapies.
Learn More
Pipeline
Esperion is a late-stage pharmaceutical company focused on developing and commercializing non-statin, convenient, complementary, consistent, once-daily, oral, LDL-C lowering therapies for the treatment of patients with hypercholesterolemia.
learn moreRECENT PRESS RELEASES
- Esperion Announces Late-Breaking Oral Presentation of Final Study 3 Results (1002-046) of Bempedoic Acid at the American Heart Association Scientific Sessions 2018
- Esperion to Participate in Upcoming Investor Conferences
- Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2018 Financial Results
Latest Tweets
moreHEARTS & MINDS BLOG
U.S. CDC Highlights High Unmet Cardiovascular Need
A new report published by the U.S. Centers for Disease Control and Prevention (CDC) sheds light on an issue that… more
Posted by Andrew JillionsInvestor Day and July Meetings Recap
Hi, I’m Alex Schwartz and I recently joined Esperion as Head of Investor Relations. Prior to joining Esperion, I was… more
Posted by mlowe@esperion.com